Wen Wan to Cost-Benefit Analysis
This is a "connection" page, showing publications Wen Wan has written about Cost-Benefit Analysis.
Connection Strength
0.613
-
The Economic Evaluation of Team Clinic-Group Approach to a Care Model of Early Adolescents With Type 1 Diabetes. J Pediatr Health Care. 2022 Sep-Oct; 36(5):430-437.
Score: 0.171
-
Cost-effectiveness of Shared Telemedicine Appointments in Young Adults With T1D: CoYoT1 Trial. Diabetes Care. 2019 08; 42(8):1589-1592.
Score: 0.138
-
Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial. Med Decis Making. 2018 11; 38(8):942-953.
Score: 0.133
-
Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial. Diabetes Care. 2018 06; 41(6):1227-1234.
Score: 0.128
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
Score: 0.043